9 Ways Menopause Accelerates Ankylosing Spondylitis Progression and What Women With SpA Need to Know
So many women with AS describe the same bewildering experience — their disease felt manageable for years, then something shifted in their late 40s and everything got harder, faster, and more painful all at once. The cruel part is that perimenopause symptoms and AS flares overlap so heavily that it can take months or years to realize the hormonal transition is pouring fuel on the fire. If that resonates, this article was written with exactly that experience in mind.
Learn more about Rose →Estrogen Directly Suppresses the TNF-Alpha Pathway — and Its Loss Removes That Brake
Tumor necrosis factor-alpha (TNF-α) is one of the primary inflammatory drivers in ankylosing spondylitis, which is precisely why TNF inhibitor biologics are a cornerstone of AS treatment. Estrogen has been shown to downregulate TNF-α signaling in synovial and spinal tissue, acting as a natural, endogenous brake on this pathway. When estrogen levels fall during perimenopause, that suppressive effect is lost and TNF-α activity can rise unchecked — effectively mimicking the inflammatory environment that biologics are prescribed to control.
IL-17 Activity Increases as Estrogen Declines, Hitting the Exact Cytokine AS Attacks
Interleukin-17 (IL-17) is the other major cytokine implicated in axial spondyloarthritis — so central to the disease that IL-17 inhibitors are a first-line biologic choice. Research shows estrogen modulates IL-17 production by T-helper cells, and falling estrogen levels are associated with an upswing in Th17-driven inflammation. For a woman with AS, perimenopause can therefore simultaneously remove two of the body's own anti-inflammatory controls at exactly the joints most vulnerable to her disease.
Sacroiliac Joint Cartilage Loses Estrogen-Dependent Protection
The sacroiliac joints are the hallmark site of early ankylosing spondylitis, and cartilage in these joints expresses estrogen receptors — meaning the tissue is directly responsive to circulating estrogen levels. Estrogen promotes proteoglycan synthesis and helps maintain cartilage matrix integrity; its withdrawal accelerates cartilage degradation in a way that compounds the existing disease-driven erosion. Women who were already showing early sacroiliac changes on imaging may see those changes progress more rapidly in the years immediately following their final menstrual period.
Bone Density Loss From Menopause Stacks Directly on Top of AS-Driven Bone Loss
Ankylosing spondylitis is already an independent risk factor for osteoporosis, driven by chronic spinal inflammation and reduced mobility — even before menopause enters the picture. The rapid bone density decline that follows estrogen withdrawal adds a second, simultaneous mechanism of bone loss, meaning women with AS face a compounded skeletal vulnerability that exceeds either condition alone. This dual pathway significantly raises fracture risk, particularly vertebral fractures in a spine already structurally compromised by the disease.
Disrupted Sleep From Hot Flashes Elevates Systemic Inflammatory Markers
Vasomotor symptoms — particularly night sweats and hot flashes — are among the most disruptive aspects of perimenopause, and fragmented sleep is a powerful independent driver of systemic inflammation. Studies consistently show that poor sleep increases circulating CRP, IL-6, and TNF-α levels, which are the same inflammatory markers that fuel AS activity. For a woman managing active axial spondyloarthritis, menopausal sleep disruption is not just exhausting — it is physiologically stoking her disease on a nightly basis.
Morning Stiffness — Already a Cardinal AS Symptom — Becomes Harder to Interpret and Manage
Prolonged morning stiffness lasting more than 45 minutes is one of the defining clinical features used to assess AS disease activity, and estrogen withdrawal independently worsens joint stiffness across the body. As perimenopause progresses, distinguishing a hormonal contribution to stiffness from genuine disease worsening becomes genuinely difficult — and this ambiguity can delay appropriate treatment escalation. Women tracking their AS disease activity scores during this transition should flag the hormonal context explicitly with their rheumatologist.
Genitourinary Changes Create New Pain Patterns That Complicate the AS Picture
The genitourinary syndrome of menopause — which includes pelvic floor changes, bladder sensitivity, and altered pelvic tissue integrity — introduces new sources of lower pelvic and sacral pain that can be almost indistinguishable from sacroiliac disease activity. This overlap means women and their clinicians may misattribute GSM-related discomfort to AS progression, or vice versa, leading to inappropriate treatment adjustments in either direction. Recognizing that both processes can coexist and independently contribute to pelvic pain is essential to managing this transition well.
Depression and Anxiety — Elevated in Both Menopause and AS — Share a Neuroinflammatory Root
Women with ankylosing spondylitis already carry significantly higher rates of depression and anxiety compared to the general population, driven in part by chronic pain and the neuroinflammatory effects of TNF-α on the central nervous system. Perimenopause independently raises depression risk through declining estrogen's effects on serotonin and dopamine signaling. When these two pathways converge, the psychological burden can become severe enough to reduce adherence to AS medications, physiotherapy, and the activity levels that are genuinely protective against spinal fusion.
HRT May Offer a Disease-Modifying Opportunity That Is Rarely Discussed in Rheumatology Clinics
Given estrogen's direct anti-inflammatory role in the joints and cytokine pathways most relevant to AS, menopausal hormone therapy represents a biologically plausible — and underexplored — adjunct for women with axial spondyloarthritis navigating this transition. Observational data suggest that HRT use in postmenopausal women is associated with lower inflammatory burden and better bone outcomes, both of which are directly relevant to AS management. Women with AS should proactively raise the question of HRT with both their rheumatologist and gynecologist, because the conversation is unlikely to happen unless they initiate it.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.